285 related articles for article (PubMed ID: 31434794)
21. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
22. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.
Cole LK; Mejia EM; Sparagna GC; Vandel M; Xiang B; Han X; Dedousis N; Kaufman BA; Dolinsky VW; Hatch GM
J Mol Cell Cardiol; 2020 Jul; 144():24-34. PubMed ID: 32418915
[TBL] [Abstract][Full Text] [Related]
23. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
[TBL] [Abstract][Full Text] [Related]
24. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome.
Acehan D; Vaz F; Houtkooper RH; James J; Moore V; Tokunaga C; Kulik W; Wansapura J; Toth MJ; Strauss A; Khuchua Z
J Biol Chem; 2011 Jan; 286(2):899-908. PubMed ID: 21068380
[TBL] [Abstract][Full Text] [Related]
25. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.
Russo S; De Rasmo D; Rossi R; Signorile A; Lobasso S
Sci Rep; 2024 Jun; 14(1):13655. PubMed ID: 38871974
[TBL] [Abstract][Full Text] [Related]
26. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
27. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
[TBL] [Abstract][Full Text] [Related]
28. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.
Hsu P; Liu X; Zhang J; Wang HG; Ye JM; Shi Y
Autophagy; 2015 Apr; 11(4):643-52. PubMed ID: 25919711
[TBL] [Abstract][Full Text] [Related]
29. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function.
Ye C; Shen Z; Greenberg ML
J Bioenerg Biomembr; 2016 Apr; 48(2):113-23. PubMed ID: 25432572
[TBL] [Abstract][Full Text] [Related]
30. Cardiolipin-deficient cells have decreased levels of the iron-sulfur biogenesis protein frataxin.
Li Y; Lou W; Grevel A; Böttinger L; Liang Z; Ji J; Patil VA; Liu J; Ye C; Hüttemann M; Becker T; Greenberg ML
J Biol Chem; 2020 Aug; 295(33):11928-11937. PubMed ID: 32636300
[TBL] [Abstract][Full Text] [Related]
31. Cardiolipin deficiency leads to the destabilization of mitochondrial magnesium channel MRS2 in Barth syndrome.
Joshi A; Gohil VM
Hum Mol Genet; 2023 Dec; 32(24):3353-3360. PubMed ID: 37721533
[TBL] [Abstract][Full Text] [Related]
32. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
33. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
34. Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens.
Dorninger F; Brodde A; Braverman NE; Moser AB; Just WW; Forss-Petter S; Brügger B; Berger J
Biochim Biophys Acta; 2015 Feb; 1851(2):117-28. PubMed ID: 25463479
[TBL] [Abstract][Full Text] [Related]
35. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
36. Phospholipid abnormalities in children with Barth syndrome.
Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
[TBL] [Abstract][Full Text] [Related]
37. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
Schlame M; Xu Y
J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
[TBL] [Abstract][Full Text] [Related]
38. Barth syndrome in a female patient.
Cosson L; Toutain A; Simard G; Kulik W; Matyas G; Guichet A; Blasco H; Maakaroun-Vermesse Z; Vaillant MC; Le Caignec C; Chantepie A; Labarthe F
Mol Genet Metab; 2012 May; 106(1):115-20. PubMed ID: 22410210
[TBL] [Abstract][Full Text] [Related]
39. Defective Mitochondrial Cardiolipin Remodeling Dampens HIF-1α Expression in Hypoxia.
Chowdhury A; Aich A; Jain G; Wozny K; Lüchtenborg C; Hartmann M; Bernhard O; Balleiniger M; Alfar EA; Zieseniss A; Toischer K; Guan K; Rizzoli SO; Brügger B; Fischer A; Katschinski DM; Rehling P; Dudek J
Cell Rep; 2018 Oct; 25(3):561-570.e6. PubMed ID: 30332638
[TBL] [Abstract][Full Text] [Related]
40. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
